Genine Winslow, CEO: 20+ years experience in successful drug discovery and development in the biotechnology industry
Professor Casey Maguire, PhD: Asst. Prof. Neurology at Harvard Medical School
Jeff Vick, MBA: 25+ years experience in gene therapy development, corporate partnerships and intellectual property
Chameleon Biosciences was founded in 2017 in California. We have an established lab and leadership team, in addition to our scientific, clinical, and regulatory advisors. Our private laboratory is inside Bonneville Labs, a coworking space for emerging biotechnology companies, community partners, and life science market leaders.
Our exclusive EVADER™ gene delivery platform technology. Innovations developed by Chameleon founders have enabled us to design a potentially more potent, less immunogenic gene therapy that overcomes existing treatment barriers.
WHY THIS MATTERS
8 million children each year are born with serious genetic disorders, which accounts for 20-30% of all infant fatalities. For those who survive, treatment options are often limited. Chameleon technology could address multiple limitations to current gene therapies. Most significantly, repeat dosing expands treatment options for more adults and children.